Bryan Johnson is a tech entrepreneur who reportedly spends about $2 million a year on a heavily monitored protocol meant to slow or reverse his biological age. His Blueprint project is part self-experiment and part business. Here is what it gets right, what remains unproven, and what applies to everyone else.
Bryan Johnson has become one of the most publicly discussed figures in longevity science - not because he is a scientist or physician, but because he has committed an extraordinary amount of money and personal discipline to testing whether the current state of longevity science, applied maximally and rigorously, can meaningfully slow or reverse biological aging in a living human being. His Blueprint project is a genuine contribution to the field as a proof-of-concept experiment. It is also, necessarily, a single-subject uncontrolled self-experiment with significant confounding from media attention, financial incentives to report positive results, and the impossibility of separating the effects of any individual intervention from the overall protocol.1
As described on his Blueprint site,1 the protocol has included a fixed early bedtime, a mostly plant-based diet built around vegetables, legumes, nuts and olive oil, dozens of supplements, daily aerobic and resistance exercise, frequent blood tests, imaging and epigenetic age testing, and periodic experimental procedures. It changes over time. In 2023 he stopped young-plasma exchange after six one-liter exchanges, saying it did not add benefit in his case.2 In late 2024 he stopped rapamycin after nearly five years, citing skin and soft tissue infections, abnormal blood lipids, raised glucose and a higher resting heart rate.6
Reports put the cost at about $2 million a year. Few people outside research studies are monitored this closely.
The foundation of Blueprint - sleep consistency, high vegetable diet, elimination of ultra-processed food, daily exercise, comprehensive biomarker tracking - is exactly what the evidence-based longevity literature recommends. These elements are not controversial. Higher cardiorespiratory fitness, for example, is strongly linked to lower long-term mortality.3 If Johnson's reported improvements are real, these are the components with the strongest evidence behind them.
The monitoring philosophy is also genuinely valuable: regular, comprehensive biomarker measurement provides feedback loops that most people lack. Tracking fasting insulin, ApoB, Lp(a), hsCRP, epigenetic age, grip strength, VO2 max, and bone density over time makes it possible to identify adverse trends and intervene before clinical disease develops. This approach to health as a measurable and optimizable system is a genuinely important conceptual contribution, even if the specific interventions Johnson uses remain experimental.
High-dose NMN: as covered in our NMN vs NR article, human trials show that NMN raises NAD+ levels and some show modest metabolic effects, but there are no long-term outcome data. Rapamycin: in mice it extended lifespan even when started late in life.4 No human trial has shown that it extends life, and Johnson stopped taking it in 2024 because of side effects.6 Young-plasma exchange: based on mouse studies in which young blood appeared to rejuvenate old tissue. In 2019 the FDA warned that infusions of plasma from young donors have no proven benefit for age-related conditions, and Johnson discontinued the exchanges after reporting no added benefit.2 Spermidine: it promotes autophagy in laboratory studies and is linked to longevity in observational data, but in a 12-month randomized trial of 100 older adults with subjective cognitive decline, spermidine supplements did not improve memory or biomarkers compared with placebo.7
Blueprint is a rigorous self-experiment by longevity standards - comprehensive monitoring, consistent protocol, self-published data. But it is fundamentally a single-subject experiment, and the limitations of n=1 experiments are not resolved by the sophistication of the monitoring. Johnson's biological age improvements could be caused by any single element of his protocol, by the combination, by regression to the mean, by the psychophysiological effects of being the focus of intense personal attention and social support, or by factors completely unrelated to his interventions. There is no control condition, no randomization, and no ability to blind. The data is real and interesting. The causal conclusions that the popular media draws from it are not justified.5
| Blueprint Element | Evidence Strength | Cost to Replicate | Verdict |
|---|---|---|---|
| Consistent 8-hour sleep schedule | Very strong RCT + cohort | Free | Do this immediately |
| High vegetable, low UPF diet | Very strong | Low to moderate | Do this immediately |
| Daily Zone 2 + resistance training | Very strong | Low (gym membership) | Do this immediately |
| Annual comprehensive bloodwork (ApoB, Lp(a), insulin, etc.) | Strong | $200-500/year | Highly recommended |
| High-dose NMN/NR | Promising, incomplete | $100-200/month | Optional, experimental |
| Intermittent rapamycin | Strong animal data, no human RCT | Requires physician | Experimental; discuss with longevity MD |
| Plasma exchange | Weak human evidence | $8,000-15,000/session | Not recommended outside trials |
Put this research into practice: Protocol Comparison Tool · Protocol Cost Calculator
